Aspire Wealth Management’s iShares Convertible Bond ETF ICVT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
$3M Sell
35,808
-1,029
-3% -$82.6K 1.61% 15
2024
Q2
$2.9M Sell
36,837
-284
-0.8% -$22.2K 1.66% 16
2024
Q1
$2.96M Sell
37,121
-57
-0.2% -$4.45K 1.79% 15
2023
Q4
$2.92M Buy
37,178
+157
+0.4% +$11.6K 1.99% 16
2023
Q3
$2.75M Buy
37,021
+1,464
+4% +$111K 2.09% 15
2023
Q2
$2.72M Buy
35,557
+95
+0.3% +$6.93K 2.05% 15
2023
Q1
$2.58M Sell
35,462
-1,399
-4% -$101K 2.09% 16
2022
Q4
$2.56M Sell
36,861
-6,694
-15% -$471K 2.23% 15
2022
Q3
$3M Buy
43,555
+786
+2% +$56.9K 2.83% 14
2022
Q2
$2.97M Buy
42,769
+124
+0.3% +$9.29K 2.73% 14
2022
Q1
$3.55M Buy
42,645
+3,157
+8% +$262K 2.81% 14
2021
Q4
$3.52M Buy
+39,488
New +$3.84M 2.85% 12

Other funds holding ICVT

Aspire Wealth Management's ICVT Position: Q3 2024 in Review

Aspire Wealth Management reduced its iShares Convertible Bond ETF (ICVT) stake by 2.8% in Q3 2024, selling an estimated $82.6K and leaving 35,808 shares worth $3M. The position accounts for 1.61% of the portfolio, ranked #15.

Aspire Wealth Management first reported a position in ICVT in Q4 2021 and has held it in 12 quarters since. The position peaked at $3.55M in Q1 2022. 302 funds tracked by Wall St. Rank hold ICVT as of Q3 2024.

  • Aspire Wealth Management held 35,808 shares of iShares Convertible Bond ETF worth $3M as of Q3 2024.
  • Aspire Wealth Management sold 1,029 iShares Convertible Bond ETF shares in Q3 2024, an estimated $82.6K.
  • iShares Convertible Bond ETF made up 1.61% of Aspire Wealth Management's portfolio in Q3 2024, its #15 holding.
  • Aspire Wealth Management first reported a position in iShares Convertible Bond ETF in Q4 2021 and has held it in 12 quarters since.
  • Aspire Wealth Management's iShares Convertible Bond ETF position peaked at $3.55M in Q1 2022.
  • 302 funds tracked by Wall St. Rank held iShares Convertible Bond ETF as of Q3 2024.

Based on Aspire Wealth Management's 13F filing for Q3 2024, filed 31 Oct 2024.